Literature DB >> 238461

Pharmacology of the esophageal motor funciton.

J Christensen.   

Abstract

In the striated muscle of the upper esophageal sphincter, tonic maintenance of closure is probably mediated via tonic central excitation of the extrinsic motor innervation; relaxation represents central inhibition of this mechanism. The motor nerves are probably cholinergic and act through nicotinic receptors like those of somatic striated muscle. In the striated muscle of the esophageal body, swallowing-induced contraction is also probably a cholinergic and nicotinic response. In the smooth muscle of the esophageal body, the control of contractions is cholinergic and muscarinic in part, but there is evidence for a nonadrenergic and noncholinergic component as well. The muscarinic component may arise from the cholinergic innervation of the longitudinal muscle layer. The other component may lie in the cryptic innervation of the circular muscular layer. In the smooth-muscled lower esophageal sphincter, resting closure tension appears to reflect a variety of possible control mechanisms. No single control system predominates. The evidence for muscarinic excitation is equivocal. An excitatory adrenergic alpha mechanism and inhibitory adrenergic beta receptors may contribute. A role for the polypeptide hormones from the gastrointestinal tract seems unlikely. Relaxation of the lower sphincter with swallowing seems not to involve any of these mechanisms, but is apparently accomplished by nonadrenergic noncholinergic inhibitory nerves like those present elsewhere in the gut (87). The possibility that the transmitter of these nerves is an adenine nucleotide has been raised from studies of other parts of the gut, but that hypothesis has not yet been examined critically in the lower esophageal sphincter.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 238461     DOI: 10.1146/annurev.pa.15.040175.001331

Source DB:  PubMed          Journal:  Annu Rev Pharmacol        ISSN: 0066-4251            Impact factor:   13.820


  9 in total

Review 1.  Swallowing: neurophysiologic control of the esophageal phase.

Authors:  A J Miller
Journal:  Dysphagia       Date:  1987       Impact factor: 3.438

2.  Effects of upper dorsal sympathectomy on esophageal motility in humans.

Authors:  E E Soffer; J Schneiderman; I Schwartz; Z Halpern; R Adar; D Weissberg; S Bar-Meir
Journal:  Dig Dis Sci       Date:  1988-02       Impact factor: 3.199

3.  Effect of hemorrhagic hypotension and hypoventilation on lower esophageal sphincter pressure.

Authors:  L K LiCalzi; P Biancani; J Behar; M D Kerstein
Journal:  Ann Surg       Date:  1980-07       Impact factor: 12.969

4.  Catecholamines release mediators in the opossum oesophageal circular smooth muscle.

Authors:  E E Daniel; L P Jager; J Jury
Journal:  J Physiol       Date:  1987-01       Impact factor: 5.182

5.  Neither a purine nor VIP is the mediator of inhibitory nerves of opossum oesophageal smooth muscle.

Authors:  E E Daniel; A Helmy-Elkholy; L P Jager; M S Kannan
Journal:  J Physiol       Date:  1983-03       Impact factor: 5.182

6.  Pharmacological dissection of the human gastro-oesophageal segment into three sphincteric components.

Authors:  James G Brasseur; Rhys Ulerich; Qing Dai; Dalipkumar K Patel; Ahmed M S Soliman; Larry S Miller
Journal:  J Physiol       Date:  2007-02-08       Impact factor: 5.182

7.  Pharmacological properties of mechanical responses of the rat oesophageal muscularis mucosae to vagal and field stimulation.

Authors:  D Bieger; C Triggle
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

8.  A missing sphincteric component of the gastro-oesophageal junction in patients with GORD.

Authors:  L Miller; Q Dai; A Vegesna; A Korimilli; R Ulerich; B Schiffner; J Brassuer
Journal:  Neurogastroenterol Motil       Date:  2009-03-13       Impact factor: 3.598

9.  Is there a biochemical basis for lower oesophageal sphincter (LOS) resting pressure?

Authors:  G Zaninotto; L Dalla Libera; S Merigliano; E Ancona
Journal:  Gut       Date:  1986-03       Impact factor: 23.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.